Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
10 pending office actions • 7 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Public University Corporation Yokohama City University has 10 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 10 examiners across 7 art units, indicating a broad prosecution footprint with repeated technical-unit assignments.
SALMON, KATHERINE D is the busiest examiner, with 1 pending matter. The breadth of the docket favors centralized oversight, while each response should remain tailored to its examiner and art-unit context.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (10%) |
| §101 + other | 1 (10%) |
| §103 only | 2 (20%) |
| Double-patenting + other | 1 (10%) |
| Multi-statute (no §101) | 5 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SALMON, KATHERINE D | 1 | 42.9% | +37.7% |
| DIETZ, NOE ROBERT | 1 | 0.0% | +0.0% |
| TRAN, LARA LINH | 1 | 16.7% | +90.9% |
| VAN BUREN, LAUREN K | 1 | 40.0% | +58.4% |
| MARMOR II, CHARLES ALAN | 1 | 12.6% | +26.3% |
| POPA, ILEANA | 1 | 21.7% | +15.7% |
| CASH, KAILEY ELIZABETH | 1 | 28.6% | +64.3% |
| ROGERS, ERIC JASON | 1 | 56.9% | +33.2% |
| GROOMS, TIFFANY NICOLE | 1 | 57.8% | +46.3% |
| MOLOYE, TITILAYO | 1 | 62.3% | +48.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17799496 | NUCLEIC ACID CONSTRUCT, AND THERAPEUTIC OR DIAGNOSTIC AGENT FOR MISMATCH REPAIR DEFICIENT CANCERS COMPRISING NUCLEIC ACID CONSTRUCT | CASH, KAILEY ELIZABETH | 49d overdue |
| 17762908 | METHOD FOR INDUCING HEPATOCYTE PLASTICITY | ROGERS, ERIC JASON | 29d |
| 18684590 | NUCLEIC ACID CONSTRUCT CAPABLE OF MEASURING HOMOLOGOUS RECOMBINATION ACTIVITY AND UTILIZATION THEREOF | SALMON, KATHERINE D | — |
| 18611777 | CANCER TREATMENT APPARATUS | DIETZ, NOE ROBERT | — |
| 18607560 | CANCER TREATMENT APPARATUS AND METHOD OF CONTROLLING CANCER TREATMENT APPARATUS | TRAN, LARA LINH | — |
| 18347886 | POWER SUPPLY APPARATUS AND MAGNETIC FIELD GENERATION SYSTEM | MARMOR II, CHARLES ALAN | — |
| 17799533 | NUCLEIC ACID CONSTRUCT THAT CAN MEASURE HOMOLOGOUS RECOMBINATION ACTIVITY, AND METHOD FOR USING SAME | POPA, ILEANA | — |
| 17251841 | Undifferentiated Cell Detection Method | GROOMS, TIFFANY NICOLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17799496 | NUCLEIC ACID CONSTRUCT, AND THERAPEUTIC OR DIAGNOSTIC AGENT FOR MISMATCH REPAIR DEFICIENT CANCERS COMPRISING NUCLEIC ACID CONSTRUCT | CASH, KAILEY ELIZABETH | 49d overdue |
| 17762908 | METHOD FOR INDUCING HEPATOCYTE PLASTICITY | ROGERS, ERIC JASON | 29d |
| 16969523 | Cell Mass Fusion Method | MOLOYE, TITILAYO | 62d |
| 18684590 | NUCLEIC ACID CONSTRUCT CAPABLE OF MEASURING HOMOLOGOUS RECOMBINATION ACTIVITY AND UTILIZATION THEREOF | SALMON, KATHERINE D | — |
| 18607560 | CANCER TREATMENT APPARATUS AND METHOD OF CONTROLLING CANCER TREATMENT APPARATUS | TRAN, LARA LINH | — |
| 18685860 | METHOD FOR CREATING FORMABLE CARTILAGE TISSUE WITHOUT REQUIRING SCAFFOLD | VAN BUREN, LAUREN K | — |
| 18347886 | POWER SUPPLY APPARATUS AND MAGNETIC FIELD GENERATION SYSTEM | MARMOR II, CHARLES ALAN | — |
| 17799533 | NUCLEIC ACID CONSTRUCT THAT CAN MEASURE HOMOLOGOUS RECOMBINATION ACTIVITY, AND METHOD FOR USING SAME | POPA, ILEANA | — |
| Art Unit | Apps |
|---|---|
| 3791 | 3 |
| 1638 | 2 |
| 1682 | 1 |
| 1633 | 1 |
| 1683 | 1 |
| 1637 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18684590 | NUCLEIC ACID CONSTRUCT CAPABLE OF MEASURING HOMOLOGOUS RECOMBINATION ACTIVITY AND UTILIZATION THEREOF | SALMON, KATHERINE D | 1682 | §101§102§103§112DP | Non-Final OA | — | Pending | Jun 24, 2024 |
| 18611777 | CANCER TREATMENT APPARATUS | DIETZ, NOE ROBERT | 3791 | §102§103§112 | Non-Final OA | — | Pending | Mar 21, 2024 |
| 18607560 | CANCER TREATMENT APPARATUS AND METHOD OF CONTROLLING CANCER TREATMENT APPARATUS | TRAN, LARA LINH | 3791 | §102§103 | Non-Final OA | — | Pending | Mar 18, 2024 |
| 18685860 | METHOD FOR CREATING FORMABLE CARTILAGE TISSUE WITHOUT REQUIRING SCAFFOLD | VAN BUREN, LAUREN K | 1638 | §103 | Final Rejection | — | Pending | Feb 22, 2024 |
| 18347886 | POWER SUPPLY APPARATUS AND MAGNETIC FIELD GENERATION SYSTEM | MARMOR II, CHARLES ALAN | 3791 | §103§112 | Non-Final OA | — | Pending | Jul 06, 2023 |
| 17799533 | NUCLEIC ACID CONSTRUCT THAT CAN MEASURE HOMOLOGOUS RECOMBINATION ACTIVITY, AND METHOD FOR USING SAME | POPA, ILEANA | 1633 | §103§112Other | Non-Final OA | — | Pending | Jan 17, 2023 |
| 17799496 | NUCLEIC ACID CONSTRUCT, AND THERAPEUTIC OR DIAGNOSTIC AGENT FOR MISMATCH REPAIR DEFICIENT CANCERS COMPRISING NUCLEIC ACID CONSTRUCT | CASH, KAILEY ELIZABETH | 1683 | §102§103§112DP | Final Rejection | 49d overdue | Pending | Dec 21, 2022 |
| 17762908 | METHOD FOR INDUCING HEPATOCYTE PLASTICITY | ROGERS, ERIC JASON | 1638 | §103§112 | Non-Final OA | 29d | Pending | Oct 07, 2022 |
| 17251841 | Undifferentiated Cell Detection Method | GROOMS, TIFFANY NICOLE | 1637 | §101 | Non-Final OA | — | Pending | Dec 14, 2020 |
| 16969523 | Cell Mass Fusion Method | MOLOYE, TITILAYO | 1632 | §103 | Final Rejection | 62d | Pending | Aug 12, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPublic University Corporation Yokohama City University has 10 pending office actions as of October 2026, spread across 7 art units and 10 examiners.
Katherine D Salmon has the most, with 1 of Public University Corporation Yokohama City University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
